Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110269 | 0.84 | FABP4 (0.34) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24109941 | 0.82 | KRAS (0.33) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24109770 | 0.82 | ADRA2A (0.32) | ADRA2AADRA2BADRA2C | |
| SCHEMBL24110196 | 0.81 | FABP4 (0.38) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24110266 | 0.79 | ADRA2A (0.30) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24109777 | 0.79 | HTR2A (0.33) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24109764 | 0.77 | HTR2A (0.32) | HTR2AHTR2C | |
| SCHEMBL24110288 | 0.77 | HTR2A (0.33) | HTR2AHTR2C | |
| SCHEMBL24110430 | 0.76 | HTR2A (0.54) | HTR2AHTR2C | |
| SCHEMBL24110322 | 0.76 | HTR2C (0.50) | P2RX7HTR2AHTR2CTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | ADRA2A 291/4885ADRA2B 659/4885ADRA2C 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.